Skip to content

Combining Local Anaesthetics with steroid: Applications in Lower Third Molar Surgeries

Combining Local Anaesthetics with Triamcinolone Acetonide: Applications in lower Third Molar Surgeries - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/088387
Enrollment
75
Registered
2025-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K039- Disease of hard tissues of teeth,unspecified

Interventions

Intervention1: Triamcinolone Acetonide 40mg with Lignocaine 2% with 1:80,000 adrenaline: this will be used as nerve block in one group as inferior alveolar nerve block Intervention2: Triamcinolone Ace

Sponsors

Dr Avni Maheshwari
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Both male and female patients Age group of 18 to 50 years Patients with impacted mandibular third molar Patients with NO systemic illness Patients not allergic to bupivacaine Patients willing to give the consent Patients willing to come for a follow-up

Exclusion criteria

Exclusion criteria: Patients above the age of 50 years Patients with erupted/non-impacted lower third molar Patients with systemic illness/immunocompromised status Patients not willing to give consent Patients allergic to triamcinolone acetonide and bupivacaine Noncompliance of patient in taking postoperative medication Inability to appear for follow-up Local pathology like cyst/tumor associated with third molar

Design outcomes

Primary

MeasureTime frame
Pain ManagmentTimepoint: 1 day, 3rd day, 7 day

Secondary

MeasureTime frame
postoperative discomfort analysisTimepoint: 1 day, 3rd day, 7th day

Countries

India

Contacts

Public ContactDr Avni Maheshwari

Jaipur dental College

avnipartani@gmail.com08764185165

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026